MIAMI BEACH, Fla., July 26, 2024 /PRNewswire/ — Immorta Bio Inc, a science-based longevity firm devoted to treating “Illnesses of Getting older and Getting older as a Illness™” with personalised mobile options, at the moment introduced the submitting of an Investigational New Drug (IND) software with the Meals and Drug Administration (FDA). The IND, which was granted #30745, is to provoke a scientific trial to judge security, immunogenicity, and efficacy alerts of SenoVax in sufferers with superior non-small cell lung most cancers. The trial will recruit sufferers who’ve failed customary therapies and can comprise of three affected person teams receiving growing doses of SenoVax.
SenoVax leverages dendritic cell know-how to enhance the pure potential of the immune system to clear senescent cells. These cells, known as “zombie cells”, are recognized to speed up the method of getting older. Within the context of most cancers, senescent cells have been demonstrated to encompass tumors and to supply a protecting aspect that “hides” cancers from immune assault1,2,3,4. Earlier research by Immorta Bio have proven that SenoVax can scale back development of lung most cancers in animal fashions and might induce immune responses that selectively kill senescent cells within the laboratory.
“To our information, that is the primary scientific candidate to push the immune system to assault not the most cancers itself, however the cells defending it,” stated Thomas Ichim, PhD, President and Chief Scientific Officer of Immorta Bio. “In distinction to most cancers, which mutates in a really fast method, senescent cells surrounding the tumor don’t mutate, thus making them a extra engaging therapeutic goal. Whereas the first intention of the research is to not examine systemic results, it will likely be of great curiosity to look at any further regenerative advantages of the SenoVax remedy, past its affect on tumor measurement discount.”
Research recommend that decreasing the variety of senescent cells utilizing small molecule approaches reduces adversarial results of the getting older course of, resembling declines in bodily5 and psychological perform6,7. As well as, it has been reported that discount of senescent cells will increase therapeutic efficacy of chemotherapy8, radiation remedy9, and immunotherapy10,11. Based mostly on latest findings, the Firm hypothesizes that immune mediated clearance of senescent cells is a extra engaging method as in comparison with small molecules since one of many pure capabilities of the immune system is to clear these cells.
“I’m grateful for our workforce, and our scientific and scientific collaborators which have taken this promising laboratory know-how and have superior it right into a candidate for scientific evaluation,” stated Boris Reznik, PhD, Chairman and CEO of Immorta Bio. Our Senolytic Immunotherapy has the potential to be invaluable not solely as a monotherapy, but additionally as an adjuvant to quite a few oncological remedies which might be at the moment within the clinic.”
About SenoVax
SenoVax is an autologous polyvalent mobile therapeutic that induces immune responses in opposition to senescent cells. It’s produced by extracting a pores and skin biopsy and creating autologous senescent cells in vitro utilizing a proprietary mechanism. These “accelerated senescent” cells are used as an antigenic supply to pulse affected person derived dendritic cells generated ex vivo. SenoVax combines the efficiency of dendritic cell immunotherapy, with the novel goal of killing tumor related senescent cells. Preclinical research have demonstrated SenoVax can scale back development of lung most cancers in animal fashions and might induce immune responses that selectively kill senescent cells within the laboratory.
About Immorta Bio
Immorta Bio is a longevity-focused biotechnology firm growing environment friendly and sensible personalised mobile therapeutic platforms centered on Treating Illnesses of Getting older and Treating Getting older as Illness™. Our therapeutic candidates goal unmet want indications throughout numerous organ methods. By growing personalised mobile therapies for aging-related ailments, we’ve the potential to considerably lengthen our sufferers’ wholesome longevity.
For extra info, please go to the Immorta Bio web site at https://www.immortabio.com or discover them on X at https://twitter.com/ImmortaBio.
Firm Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
@immortabio
Media Contacts
David Schull
Russo Companions, LLC
[email protected]
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789819/
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899869/
3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547655/
4 https://pubmed.ncbi.nlm.nih.gov/25263564
5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082705/
6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833137/
7 https://onlinelibrary.wiley.com/doi/10.1111/joim.13141
8 https://hyperlink.springer.com/article/10.1186/s43556-023-00116-4
9 https://elifesciences.org/articles/75492
10 https://www.nature.com/articles/s41467-024-46769-9#:~:textual content=Eliminationpercent20ofpercent20thesepercent20myeloidpercent20cells,thepercent20effectivenesspercent20ofpercent20cancerpercent20immunotherapies.
11 https://pubmed.ncbi.nlm.nih.gov/38794820/
SOURCE Immorta Bio, Inc
